Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients

Autor: Valentín García-Gutiérrez, Nuria Hernán, José María Guinea, Luis Felipe Casado-Montero, Gloria González, Fernando Ortega Rivas, Ana Sebrango, Angel Ramirez Payer, Miguel Piris-Villaespesa, Juan Luis Steegmann, M.A. Fernandez, Juan Carlos Hernández-Boluda, Esperanza Romero, Dragana Milojkovic, Guillermo Ortí, Sandra Valencia, Guiomar Bautista Carrascosa, Beatriz Cuevas Ruiz, Jose Manuel Puerta, Isabel Mata Vázquez, A García, Elena Amustio Díez, María-José Ramírez, Ana Iglesias Pérez, Alejandra Martínez-Trillos, Josep Maria Martí Martí-Tutusaus, José Tallón, Simone Claudiani, Concepción Boqué, Pilar Giraldo, Natalia De Las Heras Rodríguez, Angeles Portero, Maria Luisa Martin Mateos, Ana Rosell, Antonio Jiménez-Velasco, Rolando Vallansot, Jose Luis Lopez Lorenzo, Maria del Carmen García Garay, Alicia Senín, Andres Romo, Silvanna Saavedra Saavedra

Publikováno v: ANNALS OF HEMATOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

Bosutinib is a second-generation tyrosine kinase inhibitor (2GTKI) approved at 400 mg once daily (QD) as first-line therapy in patients with chronic myeloid leukemia (CML) patients and at 500 mg QD in patients who are resistant to or intolerant of pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::409aa97929066edc3abfd01bfbc0a2e8
https://pubmed.ncbi.nlm.nih.gov/30446802

Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program

Autor: Angeles Fernandez, Juan Luis Steegmann, Andrés Romo Collado, Isabel Mata, José Tallón, María José Sánchez, Ana Iglesias Pérez, Concepción Ruiz, Ana Sebrango, Jose Luis Lopez Lorenzo, Maria del Carmen García Garay, Alejandra Martínez-Trillos, Esperanza Romero, Fernando Ortega, Maria Luisa Martin Mateos, Beatriz Cuevas, Angeles Portero, José María Guinea, Valentín García-Gutiérrez, Begoña Maestro, Sandra Valencia, Pilar Giraldo, Natalia de las Heras, Sabela Bobillo, Guillermo Deben, Concepción Boqué, Alberto Alvarez-Larrán, Guiomar Bautista

Publikováno v: American Journal of Hematology. 90:429-433

The role of bosutinib as rescue treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) patients after failing three previous tyrosine kinase inhibitors (TKIs) is currently unknown. We report here the largest series (to our knowl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e575b2dea2d4f8bde015d131c52b5b9d
https://doi.org/10.1002/ajh.23973

Cytogenetic, fluorescence in situ hybridization, and molecular characterization of chronic myeloid leukemia in chronic phase with four BCR/ABL1 fusion signals: a case report

Autor: Juana Reyes, Maria Angeles Portero, María Teresa Vargas, Carmen Fernández-Novoa, Alicia Rodríguez

Publikováno v: Cancer Genetics and Cytogenetics. 195:71-74

We report a case of chronic myeloid leukemia in chronic stage with 48 chromosomes and four BCR/ABL1 fusion signals on two out of three chromosomes 9 and two signals on the two Philadelphia chromosomes. These abnormalities were detected by both conven

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a94369c3dc5dbf7a9a1cff4ff3655828
https://doi.org/10.1016/j.cancergencyto.2009.06.014

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.